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Design and characterization of antigen fused to single-chain antibody to DEC205. (A) Map of expression cassettes encoding vaccine protein 
(Vac protein) fused to single-chain scDEC and scControl. Heavy-chain (H) and light-chain (L) cDNAs of each mAb were connected by an inter-
chain linker (ICL) and cloned in frame upstream of the cDNA for OVA, HIV gag fragments (p41, p24), or GFP in a eukaryotic expression plasmid 
containing the human CMV immediate early promoter and a bovine growth hormone polyadenylation signal (pAd). LP, leader peptide; Tag, myc 
and 6× histidine tag. (B) Binding to CHO cells expressing murine DEC205 (CHOmDEC205) or CHOneo control cells of recombinant single-chain 
mAbs-OVA fusion proteins detected by an OVA-specific, FITC-labeled secondary antibody. (C) Right part shows an overlay of the binding of the 
parental bivalent antibody (DEC-OVA) compared with scDEC-OVA. (D–F) Supernatants and lysates of 293T cells transfected with expression 
plasmids for scDEC or scControl conjugated to either OVA, HIV gag p41, HIV gag p24, or empty expression plasmid (pcDNA3.1; Invitrogen) 
were Western blotted using mAbs against OVA (D) or anti-HIV gag p24 (E and F).
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To prove that MHC class I presentation by scDEC-OVA was 























or  scControl–OVA DNA. Then we  cocultured  the  cells with 
CFSE-labeled OT-I TCR transgenic T cells as reporters for suc-
Figure 2
Antigen presentation to OVA-specific T cells following in vivo targeting of DCs with OVA DNA fused to a single-chain antibody to DEC205. (A) 
Mice were immunized i.m. with graded doses of DNA, and 4 days later, 2 × 106 CFSE-labeled CD8+ OT-I or 3 × 106 CD4+ OT-II TCR transgenic T 
cells were injected i.v. At day 7, draining lymph node cells were harvested and cell division was evaluated by flow cytometry in CD4+ OT-II cells 
with Vα2 T cell receptor (20.1) antibody and in CD8+ OT-I cells with Vβ5.1/5.2+ T cell receptor (MR9-4) antibody. (A) Control mice received similar 
amounts of the scControl–OVA DNA vaccine. (B) As in A, but the experiments were performed with DEC–/–, TAP–/–, or WT B6 mice using 30 μg 
of each DNA vaccine. Representative results from 3 experiments are shown. (C) Longevity of in situ antigen presentation after vaccination with 
30 μg DNA, then evaluation by antigen presentation to 2 × 106 OT-I T cells injected at the indicated time points. (D) scDEC-OVA targets antigens 
to DCs after DNA vaccination. Mice were immunized with 30 μg of the indicated scFv DNA vaccines or backbone vector. 4 days later, CD11c+ 
and CD11c– cells were isolated and cocultured with CFSE-labeled OT-I T cells at the indicated APC to T cell ratios to determine CFSE dilution 
in vitro at day 7.5 of the experiment. (E) CD11c-DTR mice were vaccinated with 30 μg scDEC-OVA or backbone vector and were depleted of 
CD11c+ DCs 4 days later by injection of 4 ng/g of DT (DT+); then CFSE-labeled OT-1 T cells were injected to monitor antigen presentation as in 
A. C–E are representative of 2 experiments.
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Targeted DNA vaccination improves antibody responses. To evaluate 
whether scDEC-OVA vaccination would improve B cell respons-














































Targeted vaccination induces enhanced antibody responses. Antigen-specific antibody titers were determined for each mouse in a group (n = 5) 
from serum harvested at 3 or 5 weeks after vaccination with the indicated doses of DNA. (A) Titers of anti-OVA–specific isotype in B6 mice after 
1 immunization with graded doses of DNA vaccine i.m. in combination with electroporation. (B) Titers of anti-HIV gag p41 isotypes in BALB/c 
mice after 1 immunization with low doses of DNA vaccine i.m. in combination with electroporation. DNA vaccine type is displayed at the top. 
Antibody titers are expressed as group mean ± SD. Results are representative of 3 experiments.
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scDEC DNA vaccine improves HIV gag–specific T cell responses. Graded doses of the scDECp41 DNA vaccine alongside scControl DNA were 
administered i.m. in combination with electroporation to C×B6 F1 mice. 14 days later, the percentage of IFN-γ+/TNF-α+/IL-2+ T cells in gated CD3+ 
splenic T cells was assessed using a gag p41 peptide pool mix. (A) IFN-γ–secreting CD4+ and CD8+ T cells among CD3+ T cells in responses to 
unrelated peptide or HIV gag p41 peptide pool mix. (B) Cytokine profile of the primed CD4+ T cells 14 days after DNA vaccination. Cells secret-
ing 3 (arrows), 2, or 1 cytokine are indicated on the x axes. (C) Cytokine profile of the 3-μg DNA vaccine dose 28 days after vaccination as in B. 
Data are representative of 2 experiments with 2 mice pooled in each experiment.
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A single, low-dose injection of DC-targeted DNA vaccine provides protective immunity to airway challenge with vaccinia gag virus. C×B6 F1 mice 
received graded doses of scDEC and scControl HIV gag DNA vaccine, and after 3 months, they were challenged i.n. with vaccinia gag virus. (A) 
Illustrative data of average weight (left panels) and mean ± SD lung virus titers (right panels) after challenge. (B) Summary of data from a total 
of 4 different experiments (5 mice per group), 2 each in BALB/c and BALB/c × C57Bl/6 F1 mice (*P < 0.05).
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